

# FROM THE LABORATORY TO THE CLINIC: GETTING CLOSER TO A CURE?

Trinity College, Oxford

PRELIMINARY PROGRAMME - as at 19<sup>th</sup> July 2016

## WEDNESDAY 7<sup>th</sup> SEPTEMBER

SESSION 1. MICROBIAL & GENETIC APPROACHES	
SESSION 1: Chair: Marc Feldmann	
9.00	<b>REGISTRATION</b>
9.30	<b>Dan Littman</b> (NYU School of Medicine) <i>Control of T cell responses by the microbiota</i>
10.00	<b>Ramnik Xavier</b> (Massachusetts General Hospital, Boston, USA) <i>Genes, Microbes and Gut Health</i>
10.30	<b>Ying Taur</b> (Memorial Sloan Kettering Cancer Center, NY, USA) <i>Microbiome-mediated defence against intestinal infection</i>
11.00	<b>Tea/coffee break</b>
11.30	<b>Holm Uhlig</b> (NDM, Oxford, UK) <i>Autophagy defects in inflammatory bowel disease - lessons from rare diseases</i>
12.00	<b>David Leslie</b> (St Bartholomew's Hospital, London, UK) <i>The Architecture of Autoimmune Diabetes</i>
12.30	<b>John Todd</b> (Univ. of Cambridge, UK) <i>Identifying and understanding pathways to target in treatment and prevention of type 1 diabetes</i>
1.00	<b>LUNCH</b>
SESSION 2. INFLAMMATION & EPIGENETICS	
SESSION 2: Chair: Larry Steinman	
2.00	<b>Luke O'Neill</b> (Trinity College Dublin, Ireland) <i>Metabolic reprogramming in innate immunity and Inflammation</i>
2.30	<b>Katja Simon</b> (Kennedy Institute, Oxford, UK) <i>Autophagy in differentiation of immune cells</i>
3.00	<b>Laura Lee Dugan</b> (Vanderbilt Univ., Nashville, TN, USA) <i>A new class of catalytic anti-inflammatory compounds for CNS applications</i>
3.30	<b>Tea/coffee break</b>
4.00	<b>Anne Schaefer</b> (Icahn School of Medicine, NY, USA) <i>Epigenetic control of neurodegeneration</i>
4.30	<b>Phil Chamberlain</b> (Celgene - San Diego, USA) <i>Cereblon modulators</i>
5.00	<b>Sasha Tarakhovsky</b> (Rockefeller Univ., NY, USA) <i>Epigenetic impact of pathogenic viruses</i>

## THURSDAY 8<sup>th</sup> SEPTEMBER

SESSION 3. CANCER	
SESSION 3: Chair: Enzo Cerundolo	
9.00	<b>Larry Gold</b> (SomaLogic, Boulder, Colorado, USA) <i>Large Scale Proteomic Measurements for the Drug Development Pathway</i>
9.30	<b>Bent Jakobsen</b> (Immunocore, Abingdon, UK) <i>ImmTACs: Bi-specific TCR-based reagents for targeted cancer immunotherapy</i>
10.00	<b>Shannon Turley</b> (Genentech, USA) <i>Stromal-Immuncyte Interactions in Lymphoid Organs and Beyond</i>
10.30	<b>Shu-Hsia Chen</b> (Icahn School of Medicine, NY, USA) <i>The plasticity of myeloid cell differentiation</i>
11.00	<b>Tea/coffee break</b>
11.30	<b>Duane Mitchell</b> (Univ. of Florida, USA) <i>Brain tumour immunotherapy</i>
12.00	<b>Cornelius Melief</b> (ISA Pharmaceuticals, Leiden, Netherlands) <i>Combination chemo-immunotherapy of disease caused by high risk human papilloma virus</i>
12.30	<b>Mike Shepard</b> (Halozyme) <i>Tumor-microenvironment based drug discovery</i>
1.00	<b>LUNCH</b>
2.00	<b>Charles Craddock</b> (Queen Elizabeth Hospital, Birmingham,, UK) <i>(1) Extending the curative potential of stem cell transplantation; (2) New drug and transplant therapies in acute myeloid leukaemia</i>
SESSION 4. STROMAL & NOVEL APPROACHES	
SESSION 4: Chair: Tom Daniel	
2.30	<b>Bente Klarlund Pedersen</b> (Centre of Inflammation & Metabolism - Copenhagen, Denmark) <i>Exercise as Medicine</i>
3.00	<b>Percio Gulko</b> (Icahn School of Medicine, NY, USA) <i>Understanding the fibroblast-like synoviocytes behaviour to generate new treatments for rheumatoid arthritis</i>
3.30	<b>Tea/coffee break</b>
4.00	<b>Chris Buckley</b> (Queen Elizabeth Hosp., Birmingham, UK) <i>Targeting fibroblasts to treat arthritis</i>
4.30	<b>Mone Zaidi</b> (MSSM, New York, USA) <i>Can a single therapeutic cure both osteoporosis and obesity in post-menopausal women?</i>
7.00 pm	<b>CONFERENCE DINNER</b>

## FRIDAY 9<sup>th</sup> SEPTEMBER

SESSION 5. HUMAN IMMUNOLOGY	
SESSION 5: Chair: Fiona Powrie	
8.30	<b>Nicole Zitzmann</b> (Oxford) <i>Developing broad-spectrum iminosugar antivirals - Focusing on ER alpha glucosidase II</i>
9.00	<b>Susan Kaech</b> (Yale Univ. School of Medicine, USA) <i>Fattening up T cells</i>
9.30	<b>Donna Farber</b> (Columbia Univ Med Center, NY, USA) <i>Human immune responses in tissues and circulation</i>
10.00	<b>Andrew McMichael</b> (NDMRB, Oxford, UK) <i>Antigen presentation by HLA-E</i>
10.30	<b>Louis Picker</b> (OHSU, OR, USA) <i>Programming CD8+ T Cell Immunity: Lessons from Cytomegalovirus"</i>
11.00	<b>Tea/coffee break</b>
11.30	<b>Harvey Cantor</b> (Dana Farber Cancer Inst. Boston, USA) <i>Helios, Treg stability and cancer immunotherapy</i>
12.00	<b>Tom Ottenhoff</b> (Leiden Univ Med Center, Leiden, Netherlands) <i>Role of non-classical T cells in infectious disease.</i>
12.30	<b>Carl June</b> (University of Pennsylvania, USA) <i>Adoptive transfer therapy for cancer</i>
1.00	<b>LUNCH</b>
SESSION 6. REGULATION OF ADAPTIVE IMMUNITY	
SESSION 6: Chair: Ravinder Maini and Jim Woody	
2.00	<b>Vivianne Malmström</b> (Karolinska Institute, Stockholm, Sweden) <i>Neo-antigen recognition in Rheumatoid Arthritis - BCR and TCR studies of citrulline autoimmunity</i>
2.30	<b>Patrick Venables</b> (Kennedy Institute, Oxford, UK) <i>Inhibition of citrullination: getting nearer to a cure?</i>
3.00	<b>Larry Steinman</b> (Stanford University, USA) <i>From bile to fatty acids: Immune regulation via modulation of nuclear hormone receptors</i>
3.30	<b>Tea/coffee break</b>
4.00	<b>Doreen Cantrell</b> , (University of Dundee) <i>Metabolic and transcriptional regulation of CD8 cell function</i>
4.30	<b>Kari Nadeau</b> (Stanford University, USA) <i>Mechanisms of Immune Tolerance in Immunotherapy</i>
5.00	<b>David Hafler</b> (Yale Univ. School of Medicine, USA) <i>Regulation of Autoimmune Responses</i>
5.30	<b>Shimon Sakaguchi</b> (Kyoto University, Japan) <i>Targeting regulatory T cells for cancer immunotherapy</i>

